Julia Chisholm

<i>DICER1</i> syndrome: clarifying the diagnosis, clinical features and management implications of a pleiotropic tumour predisposition syndrome

I. Slade, Chiara Bacchelli, H. Davies et al. · Journal of Medical Genetics · 2011 · 361 citations · Full text

Vinorelbine and continuous low-dose cyclophosphamide as maintenance chemotherapy in patients with high-risk rhabdomyosarcoma (RMS 2005): a multicentre, open-label, randomised, phase 3 trial

Gianni Bisogno, Gian Luca De Salvo, Christophe Bergeron et al. · The Lancet Oncology · 2019 · 231 citations · Full text

Oncology, Metronomic Therapy, Rms 2005 +9

Genomic Classification and Clinical Outcome in Rhabdomyosarcoma: A Report From an International Consortium

Jack F. Shern, Joanna Selfe, Elisa Izquierdo et al. · Journal of Clinical Oncology · 2021 · 199 citations · Full text

Addition of dose-intensified doxorubicin to standard chemotherapy for rhabdomyosarcoma (EpSSG RMS 2005): a multicentre, open-label, randomised controlled, phase 3 trial

Gianni Bisogno, Meriel Jenney, Christophe Bergeron et al. · The Lancet Oncology · 2018 · 182 citations

Oncology, Medicine, Dose-intensified Doxorubicin +10

Phase I study of oral sonidegib (LDE225) in pediatric brain and solid tumors and a phase II study in children and adults with relapsed medulloblastoma

Mark W. Kieran, Julia Chisholm, Michela Casanova et al. · Neuro-Oncology · 2017 · 166 citations · Full text